Show simple item record

dc.contributor.authorLarsen, Stein Gunnar
dc.contributor.authorGoscinski, Mariusz Adam
dc.contributor.authorDueland, Svein
dc.contributor.authorSteigen, Sonja Eriksson
dc.contributor.authorHofsli, Eva
dc.contributor.authorTorgunrud, A.
dc.contributor.authorLund-Iversen, Marius
dc.contributor.authorDagenborg, Vegar Johansen
dc.contributor.authorFlatmark, Kjersti
dc.contributor.authorSorbye, Halfdan
dc.description.abstractBackground Patients with metastatic colorectal cancer (mCRC) carrying BRAF (mutBRAF) or KRAS mutation (mutKRAS) have an inferior prognosis after liver or lung surgery, whereas the prognostic role in the context of peritoneal metastasis (PM) after cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) has been less investigated. Methods In total, 257 patients with non-appendiceal PM-CRC were included from the Norwegian National Unit for CRS-HIPEC. Results In total, 180 patients received CRS-HIPEC with Mitomycin C, 77 patients received palliative surgery only. In the CRS-HIPEC group, mutBRAF was found in 24.7%, mutKRAS 33.9% and double wild-type 41.4% without differences in survival. MSI was found in 29.3% of mutBRAF cases. Patients with mutBRAF/MSI had superior 5-year survival compared to mutBRAF with MSS (58.3% vs 25.2%, P = 0.022), and better 3-year disease-free survival (DFS) compared to mutKRAS (48.6% vs 17.2%, P = 0.049). Peritoneal Cancer Index and the number of lymph node metastasis were prognostic for OS, and the same two, location and gender prognostic for DFS in multivariate analysis. Conclusions PM-CRC with CRS-HIPEC patients has a surprisingly high proportion of mutBRAF (24.7%). Survival was similar comparing mutBRAF, mutKRAS and double wild-type cases, whereas a small subgroup with mutBRAF and MSI had better survival. Patients with mutBRAF tumours and limited PM should be considered for CRS-HIPEC.en_US
dc.rightsNavngivelse 4.0 Internasjonal*
dc.titleImpact of KRAS, BRAF and microsatellite instability status after cytoreductive surgery and HIPEC in a national cohort of colorectal peritoneal metastasis patientsen_US
dc.typeJournal articleen_US
dc.typePeer revieweden_US
dc.rights.holder© The Author(s) 2021en_US
dc.source.journalBritish Journal of Canceren_US
dc.identifier.citationBritish Journal of Cancer. 2021.en_US

Files in this item


This item appears in the following Collection(s)

Show simple item record

Navngivelse 4.0 Internasjonal
Except where otherwise noted, this item's license is described as Navngivelse 4.0 Internasjonal